14 active not recruiting, 7 recruiting, 3 not yet recruiting, 2 completed. 30 Phase 1, 12 Phase 2.
Follow Ruxience: new trials by email Literature Review of Ruxience trials Research Report on Ruxience
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| AMC 120, Glofitamab Plus Chemoimmunotherapy in Newly Diagnosed HIV-Associated Large B-Cell Lymphoma (The "Glofit-RCHOP Study") Biopsy Procedure, Biospecimen Collection, Bone Marrow Aspiration - AIDS-Related Diffuse Large B-cell Lymphoma, Diffuse Large B-Cell Lymphoma, Not Otherwise Specified | Phase 1 | Recruiting | National Cancer Institute (NCI) | 15 | 2027-07-05 | 2026-10-28 |
| Golcadomide in Combination With Rituximab for the Treatment of Patients With Relapsed or Refractory Mantle Cell Lymphoma Biopsy Procedure, Biospecimen Collection, Bone Marrow Biopsy - Recurrent Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma | Phase 1 / Phase 2 | Recruiting | City of Hope Medical Center | 58 | 2026-12-21 | 2026-10-22 |
| Epcoritamab and Pola-R-mini-CHP for the Treatment of Diffuse Large B Cell Lymphoma in Elderly or Unfit Patients Biospecimen Collection, Computed Tomography, Cyclophosphamide - Diffuse Large B-Cell Lymphoma, Grade 3b Follicular Lymphoma | Phase 1 | Not yet recruiting | Jonsson Comprehensive Cancer Center | 20 | 2026-12-08 | 2026-07-20 |
| Loncastuximab Tesirine and Rituximab as First-line Therapy in Patients With Post-transplant Lymphoproliferative Disorder (PLUTO) Loncastuximab tesirine, Rituximab or rituximab biosimilar - Post-transplant Lymphoproliferative Disorder | Phase 1 / Phase 2 | Not yet recruiting | University of Utah | 23 | 2026-11-01 | 2026-10-09 |
| Testing the Addition of an Anti-Cancer Drug, Glofitamab, to the Usual Chemotherapy Treatment (Alternating R-CHOP/R-DHAP) for Previously Untreated Mantle Cell Lymphoma Biospecimen Collection, Cisplatin, Computed Tomography - Ann Arbor Stage II Mantle Cell Lymphoma, Ann Arbor Stage III Mantle Cell Lymphoma | Phase 1 | Not yet recruiting | National Cancer Institute (NCI) | 16 | 2026-10-30 | 2026-09-03 |
| Testing the Combination of Anti-cancer Drugs, Tovorafenib Plus Rituximab, in Patients With Hairy Cell Leukemia Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Hairy Cell Leukemia, Recurrent Hairy Cell Leukemia | Phase 1 / Phase 2 | Recruiting | National Cancer Institute (NCI) | 84 | 2026-05-29 | 2026-07-31 |
| Tazemetostat in Combination With Zanubrutinib and Anti-CD20 Monoclonal Antibody in Relapsed or Refractory B-cell Non-Hodgkin Lymphoma Zanubrutinib, Rituximab, Obinutuzumab - Relapsed or Refractory B-cell Non-Hodgkin Lymphoma | Phase 1 | Active not recruiting | University of Utah | 24 | 2025-09-12 | 2026-06-30 |
| Roginolisib (IOA-244) With Venetoclax and Rituximab for Refractory/Relapsed Chronic Lymphocytic Leukemia (CLL) Roginolisib, Venetoclax, Rituximab - Leukemia, Relapsed Leukemia | Phase 1 / Phase 2 | Recruiting | Jennifer R. Brown, MD, PhD | 64 | 2025-03-19 | 2026-02-11 |
| Pembrolizumab + Chemotherapy in Newly Diagnosed PCNSL Pembrolizumab, Methotrexate, Temozolomide - Lymphoma, Primary Central Nervous System Lymphoma | Phase 1 | Recruiting | Dana-Farber Cancer Institute | 15 | 2024-10-18 | 2026-10-23 |
| CC-99282 + Rituximab Early Post CART for Non-Hodgkin's Lymphoma Biopsy, Biospecimen Collection, Computed Tomography - B-Cell Non-Hodgkin Lymphoma-Recurrent, Diffuse Large B-Cell Lymphoma-Recurrent | Phase 1 | Recruiting | Nathan Denlinger | 18 | 2024-01-29 | 2026-02-27 |
| FT522 With Rituximab in Relapsed/Refractory B-Cell Lymphoma (FT522-101) FT522, Rituximab, Cyclophosphamide - Relapsed/Refractory B-Cell Lymphoma | Phase 1 | Completed | Fate Therapeutics | 20 | 2023-11-16 | 2025-08-22 |
| Siplizumab for Sickle Cell Disease Transplant Siplizumab, Exchange Transfusion, Total Body Irradiation - Anemia, Sickle Cell | Phase 1 / Phase 2 | Terminated | Columbia University | 1 | 2023-09-28 | 2026-06-10 |
| FT596 in Combination With R-CHOP in Subjects With B-Cell Lymphoma FT596, Cyclophosphamide, Doxorubicin - Diffuse Large B Cell Lymphoma, Transformed Indolent Non-Hodgkin's Lymphoma | Phase 1 | Withdrawn | Fate Therapeutics | 2022-12-01 | 2023-07-06 | |
| Venetoclax, Dasatinib, Prednisone, Rituximab and Blinatumomab for the Treatment of Newly Diagnosed or Relapsed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia or Mixed Phenotype Acute Leukemia Dasatinib, Methotrexate, Prednisone - B Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1 | Phase 1 | Active not recruiting | OHSU Knight Cancer Institute | 20 | 2022-09-02 | 2026-05-06 |
| Testing the Addition of Lenalidomide and Nivolumab to the Usual Treatment for Primary CNS Lymphoma Bone Marrow Aspiration and Biopsy, Computed Tomography, Echocardiography Test - Primary Diffuse Large B-Cell Lymphoma of the Central Nervous System | Phase 1 | Active not recruiting | National Cancer Institute (NCI) | 47 | 2021-05-24 | 2026-10-19 |
| Polatuzumab Vedotin and Combination Chemotherapy With or Without Glofitamab for the Treatment of Untreated Aggressive Large B-cell Lymphoma Polatuzumab Vedotin, Rituximab, Prednisone - Aggressive Non-Hodgkin Lymphoma, ALK-Positive Large B-Cell Lymphoma | Phase 1 / Phase 2 | Active not recruiting | University of Washington | 56 | 2020-10-27 | 2026-10-02 |
| Parsaclisib Plus the Standard Drug Therapy in Patients With Newly Diagnosed, High Risk Diffuse Large B-cell Lymphoma Cyclophosphamide, Doxorubicin Hydrochloride, Parsaclisib - Ann Arbor Stage II Diffuse Large B-Cell Lymphoma, Ann Arbor Stage II Follicular Lymphoma | Phase 1 | Active not recruiting | Mayo Clinic | 50 | 2020-06-15 | 2026-02-02 |
| FT596 as a Monotherapy and in Combination With Anti-CD20 Monoclonal Antibodies FT596, Cyclophosphamide, Fludarabine - Lymphoma, B-Cell, Chronic Lymphocytic Leukemia | Phase 1 | Terminated | Fate Therapeutics | 98 | 2020-03-19 | 2023-10-26 |
| Moxetumomab Pasudotox-tdfk (Lumoxiti(TM)) and Either Rituximab (Rituxan(R)) or Ruxience for Relapsed Hairy Cell Leukemia Moxetumomab Pasudotox-tdfk, Rituximab, Ruxience - Hairy Cell Leukemia | Phase 1 | Active not recruiting | National Cancer Institute (NCI) | 18 | 2019-10-03 | 2026-06-29 |
| Testing the Addition of an Immunotherapy Agent, Atezolizumab, When Given With the Usual Chemo-Immunotherapy Drug Combination (Rituximab Plus Gemcitabine and Oxaliplatin) for Relapsed/Refractory (That Has Come Back or Not Responded to Treatment) Transformed Diffuse Large B-Cell Lymphoma Atezolizumab, Biopsy Procedure, Biospecimen Collection - Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Transformed Non-Hodgkin Lymphoma | Phase 1 | Active not recruiting | National Cancer Institute (NCI) | 24 | 2018-09-18 | 2026-06-11 |
Showing 20 of 30. Sign in to see all of them.
Lymphoma, Large B-Cell, Diffuse (7) · Lymphoma, B-Cell (6) · Leukemia (3) · Leukemia, Lymphocytic, Chronic, B-Cell (3) · Lymphoma (3) · Lymphoma, Mantle-Cell (3) · Leukemia, Hairy Cell (2) · Lymphoma, AIDS-Related (2) · Lymphoma, Primary Effusion (2) · Recurrence (2) · Anemia, Sickle Cell (1) · Burkitt Lymphoma (1) · Disease (1) · Hodgkin Disease (1) · Leukemia, Biphenotypic, Acute (1)
National Cancer Institute (NCI) (13) · Fate Therapeutics (3) · University of Utah (2) · Academic and Community Cancer Research United (1) · BioInvent International AB (1) · City of Hope Medical Center (1) · Columbia University (1) · Dana-Farber Cancer Institute (1) · Jennifer R. Brown, MD, PhD (1) · Jonsson Comprehensive Cancer Center (1) · M.D. Anderson Cancer Center (1) · Mayo Clinic (1) · Nathan Denlinger (1) · OHSU Knight Cancer Institute (1) · University of Washington (1)
United States (28) · Brazil (1) · Germany (1) · Poland (1) · Spain (1) · Sweden (1)
Alain Mina, M.D. (1) · Alex F Herrera (1) · Alvaro J Alencar (1) · Bouthaina S Dabaja (1) · Catherine S Diefenbach (1) · Chaitra S Ujjani (1) · Daniel O Persky (1) · Grzegorz S Nowakowski (1) · Ida C Wong-Sefidan (1) · Jennifer Brown, MD, PhD (1) · Jessica T Leonard (1) · Kieron Dunleavy (1) · Lakshmi Nayak, MD (1) · Markus Y Mapara, MD, PhD (1)
PMID 27697771, PMID 35787017, PMID 36521030, PMID 39798981, PMID 40331908, PMID 40802906
U10CA180821 (2), UM1CA121947 (2), UM1CA186717 (2), 2015 (1), P30CA013330 (1), P30CA015083 (1), P30CA033572 (1), P30CA051008 (1), U10CA031946 (1), U10CA032102 (1), U10CA180888 (1), UM1CA186712 (1)